https://www.fda.gov/news-events/press-announcements/fda-approves-oral-treatment-spinal-muscular-atrophy
FDA Approves Oral Treatment for Spinal Muscular Atrophy
Evrysdi (risdiplam)
www.SMATreatmentReport.com
https://www.fda.gov/news-events/press-announcements/fda-approves-oral-treatment-spinal-muscular-atrophy
FDA Approves Oral Treatment for Spinal Muscular Atrophy
Evrysdi (risdiplam)
https://clinicaltrials.gov/ct2/show/NCT02913482?type=Intr&cond=spinal+muscular+atrophy&phase=0124&lupd_s=07%2F08%2F2020&lupd_d=14&sort=nwst
STUDY TITLE:
Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy
DESCRIPTION:
Condition: Muscular Atrophy, Spinal
Intervention: Drug: Risdiplam
Sponsor: Hoffmann-La Roche
Active, not recruiting
CLINICALTRIALS.GOV IDENTIFIER:
NCT02913482
FIRST POSTED:
Fri, 23 Sep 2016 12:00:00 EDT
LAST UPDATE POSTED:
07/22/20 08:23AM
STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT02913482?type=Intr&cond=spinal+muscular+atrophy&phase=0124&lupd_s=07%2F08%2F2020&lupd_d=14&sort=nwst
https://clinicaltrials.gov/ct2/show/NCT02908685?type=Intr
https://clinicaltrials.gov/ct2/show/NCT02908685?type=Intr&cond=Spinal+Muscular+Atrophy&lupd_s=06%2F19%2F2020&lupd_d=14&sort=nwst
STUDY TITLE:
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants
DESCRIPTION:
Condition: Muscular Atrophy, Spinal
Interventions: Drug: Placebo; Drug: Risdiplam
Sponsor: Hoffmann-La Roche
Active, not recruiting
CLINICALTRIALS.GOV IDENTIFIER:
NCT02908685
FIRST POSTED:
Wed, 21 Sep 2016 12:00:00 EDT
LAST UPDATE POSTED:
07/03/20 07:39PM
STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT02908685?type=Intr&cond=Spinal+Muscular+Atrophy&lupd_s=06%2F19%2F2020&lupd_d=14&sort=nwst
https://clinicaltrials.gov/ct2/show/NCT03032172?type=Intr&cond=spinal+muscular+atrophy&phase=0124&lupd_s=07%2F07%2F2020&lupd_d=14&sort=nwst
STUDY TITLE:
A Study of Risdiplam (RO7034067) in Adult and Pediatric Participants With Spinal Muscular Atrophy
DESCRIPTION:
Condition: Spinal Muscular Atrophy
Intervention: Drug: Risdiplam
Sponsor: Hoffmann-La Roche
Active, not recruiting
CLINICALTRIALS.GOV IDENTIFIER:
NCT03032172
FIRST POSTED:
Thu, 26 Jan 2017 12:00:00 EST
LAST UPDATE POSTED:
07/21/20 08:07AM
STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03032172?type=Intr&cond=spinal+muscular+atrophy&phase=0124&lupd_s=07%2F07%2F2020&lupd_d=14&sort=nwst
https://finance.yahoo.com/news/roche-provides-regulatory-risdiplam-treatment-200500098.html
Roche provides regulatory update on risdiplam for the treatment of spinal muscular atrophy (SMA)